Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.
Saved in:
| Title: | Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. |
|---|---|
| Authors: | Chheda ZS; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA., Kohanbash G; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA.; Department of Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA., Okada K; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA., Jahan N; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA., Sidney J; Center for Infectious Disease, Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA., Pecoraro M; Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany., Yang X; Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA., Carrera DA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA., Downey KM; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA., Shrivastav S; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA., Liu S; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA., Lin Y; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA., Lagisetti C; Department of Public Health, University of California, Berkeley, Berkeley, CA., Chuntova P; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA., Watchmaker PB; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA., Mueller S; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA., Pollack IF; Department of Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA., Rajalingam R; Department of Surgery, Immunogenetics and Transplantation Laboratory, University of California, San Francisco, San Francisco, CA., Carcaboso AM; Institut de Recerca Sant Joan de Deu, Barcelona, Spain., Mann M; Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany., Sette A; Center for Infectious Disease, Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA., Garcia KC; Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA.; Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA.; Department of Structural Biology, Stanford University School of Medicine, Stanford, CA., Hou Y; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA., Okada H; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA hideho.okada@ucsf.edu.; Cancer Immunotherapy Program, University of California, San Francisco, San Francisco, CA.; The Parker Institute for Cancer Immunotherapy, San Francisco, CA. |
| Source: | The Journal of experimental medicine [J Exp Med] 2018 Jan 02; Vol. 215 (1), pp. 141-157. Date of Electronic Publication: 2017 Dec 04. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Rockefeller University Press Country of Publication: United States NLM ID: 2985109R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1540-9538 (Electronic) Linking ISSN: 00221007 NLM ISO Abbreviation: J Exp Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
